๐
Kygevvi
doxecitine;doxribtimine
Mitochondrial Diseases
โ
Authorised
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/kygevvi